One stock in the cannabis patch that might offer some opportunities this coming week is Emerald Health Therapeutics Inc (OTCMKTS:EMHTF). To wit: a major partner of the company, MediPharm Labs Corp., just announced that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales license from Health Canada pursuant to the Cannabis Act.
According to the release, the sales license relates to the company’s wholly-owned laboratory and manufacturing facilities in Barrie, Ontario. “This Sales License represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.
Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) trumpets itself as a licensed producer of medical marijuana under the Access to Cannabis for Medical Purposes Regulations, which allows the company to produce and sell medical marijuana and cannabis oils to clients and other licensed producers.
Individuals may become clients of the company by registering with the company through its secure online portal or via telephone after the individual has received a medical document signed by a licensed health care practitioner setting out the daily quantity of dried marijuana, in grams, that the practitioner authorized for the person.
According to company materials, “Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) operates through Emerald Health Botanicals Inc., a wholly owned subsidiary and Licensed Producer under the Access to Cannabis for Medical Purposes Regulations. Botanicals is authorized to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. Botanicals currently operates an indoor facility in Victoria, BC, and is progressing on expansion plans for a 32-acre property in Metro Vancouver and a partnership with Village Farms, called Pure Sunfarms, utilizing a 25-acre existing greenhouse complex in Delta, BC. Botanicals is one of Canada’s most medically focused licensed producers, with a team highly experienced in life sciences product development and large-scale agribusiness. Its vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics, value-added products and branding, and superb customer experience. Emerald Health Therapeutics is associated with the Emerald Health group, which comprises multiple companies advancing diverse botanical, nutraceutical and pharmaceutical products that may provide wellness and medical benefits by interacting with the body’s endocannabinoid system.”
Find out when $EMHTF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, EMHTF just announced that a major partner of the company, MediPharm Labs Corp., just received its sales license from Health Canada pursuant to the Cannabis Act.
According to the release, MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification. MediPharm Labs currently operates one of the largest cannabis concentrate manufacturing facilities in Canada and is built to cGMP (current Good Manufacturing Practices) and ISO standards. Leveraging MediPharm Lab’s proprietary pharmaceutical manufacturing expertise, the Company currently has Phase 1 capacity to process over 100,000 kg of dry cannabis per year. With Phase 2 funded and expected to be completed by the end of Q2 2019, the Company anticipates that its processing capacity will more than double to up to 250,000 kg annually upon the completion of such expansion.
The deal between EMHTF and MediPharm is a 3-year agreement announced on October 10 that stipulates EMHTF will provide MediPharm with dried cannabis to create premium quality cannabis oil. The establishment of the sales license should set the demand process into motion and further energize operations at Emerald.
If this helps to spur some action on the EMHTF chart, then we could quickly see a test of the major MA’s above in the $3.50 area.
Earning a current market cap value of $405.18M, EMHTF has a significant war chest ($72.7M) of cash on the books, which is balanced by about $26.3M in total current liabilities. One should also note that debt has been growing over recent quarters. EMHTF is pulling in trailing 12-month revenues of $1.1M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 15.7%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $EMHTF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $EMHTF, either long or short, and we have not been compensated for this article.